Evidence map›Paper›PMID 34513052›Full record

ArticleSovremennye tekhnologii v meditsine2020

Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma.

Z V Amoev, A V Alyasova, T N Gorshkova, E I Samsonova, E V Strokina, K N Kontorshchikova

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. The moonlighting functions of glycolytic enzymes in tumorigenesis.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Z V AmoevUrologist, Department of Urology No.2, Clinical Hospital No.1, Privolzhsky District Medical Center of Federal Medico-Biologic Agency of Russia, 14 Ilyinskaya St., Nizhny Novgorod, 603000, Russia.
A V AlyasovaProfessor, Department of Oncology, Radiation Therapy and Radiology, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
T N GorshkovaHead of Clinical Diagnostic Laboratory, Privolzhsky District Medical Center of Federal Medico-Biologic Agency of Russia, 14 Ilyinskaya St., Nizhny Novgorod, 603000, Russia.
E I SamsonovaPhysician, Clinical Diagnostic Laboratory, Privolzhsky District Medical Center of Federal Medico-Biologic Agency of Russia, 14 Ilyinskaya St., Nizhny Novgorod, 603000, Russia.
E V StrokinaPhysician, Clinical Diagnostic Laboratory, Privolzhsky District Medical Center of Federal Medico-Biologic Agency of Russia, 14 Ilyinskaya St., Nizhny Novgorod, 603000, Russia.
K N KontorshchikovaProfessor, Head of the Department of Clinical Laboratory Diagnostics, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
Privolzhsky Research Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MATERIALS AND

methodsSamples of blood plasma or serum of 46 patients with clear cell renal cancer T

resultsIn patients with renal cell carcinoma, a statistically significant increase in the level of Tu M2-PK, CA9 and a statistically significant decrease in MMP9 in comparison with the control group were found. The level of Tu M2-PK in patients with localized kidney cancer was significantly lower than in patients with disseminated cancer. An increase in size of the primary tumor and a decrease in the degree of its differentiation correlated with an increase in Tu M2-PK, and decrease in CA9 and MMP9 in the blood serum. Performing surgery equivalent to nephrectomy did not change the Tu M2-PK levels in the early postoperative period, but caused a decrease in the levels of CA9 and MMP9.

conclusionThe results indicate a potential significance of Tu M2-PK, CA9, and MMP9 as biological markers for predicting the disease course in patients with renal cell carcinoma.

Indexed as

markers of renal cell carcinomamatrix carbonic anhydrase IXmetalloproteinase 9renal cell carcinomatumor M2-pyruvate kinase

Identifiers

PMID34513052
PMCPMC8353685
OpenAlexW3022587764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.